Richard Mair joins Institute as an Independent Clinical Fellow
Richard Mair has joined the Cancer Research UK Cambridge Institute as an Independent Clinical Fellow.
Dr Richard Mair is the first to be appointed under the Institute’s new Independent Clinical Fellow Programme, which supports clinician scientists in establishing themselves as independent clinical academics and future leaders in their field.
The programme provides fellows with access to world-class research facilities, dedicated mentorship, and operational support, enabling them to build their own research groups and advance translational cancer research.
Richard is Assistant Professor of Neurosurgical Oncology at the University of Cambridge and an Honorary Consultant Neurosurgeon at Addenbrooke’s Hospital. He leads several key initiatives, including the Minderoo Precision Brain Tumour Programme, the Brain Cancer Virtual Institute at the CRUK Cambridge Centre and the ICARUS tissue bank.
Supported by a Cancer Research UK Advanced Clinician Scientist Fellowship, Richard will build a research group at the Institute to focus on IDH mutant astrocytoma, a common type of brain tumour that accounts for 9% of brain tumour diagnoses.
Astrocytoma typically presents as a slow growing, low-grade tumour, before undergoing a transformation to a high-grade, fast-growing tumour. Once this transformation occurs, the average patient survival is approximately 2 years.
Richard and his team at the Institute will investigate why astrocytoma transforms from a low-grade to a high-grade tumour. Their work will particularly focus on metabolic and epigenomic interplay in this process. They aim to identify key genes that drive transformation and to develop novel therapeutic strategies that could improve patient outcomes.
“We are delighted to welcome Dr Richard Mair as the first fellow appointed under our Independent Clinical Fellow Programme. Through his leadership in the Minderoo Precision Brain Tumour Programme as well as his work on the 5G platform trial, Richard has demonstrated a strong drive to bridge cutting-edge research with real-world clinical impact. His track record of translating discoveries into real benefits for patients makes him an outstanding addition to the Institute, and we are excited to support him as he builds his research group to further advance brain tumour research.”
Dr Raza Ali, Associate Director for Clinical Academic Training
Related News
See all news-
Dr Guiping Wang appointed as a Junior Group Leader
18th May 2026
Dr Guiping Wang joins the Cancer Research UK Cambridge Institute as a Junior Group Leader, starting in September 2026.
Find out more -
Shankar Balasubramanian receives the Princess of Asturias Award for Scientific and Technical Research
14th May 2026
The 2026 award recognises Prof Balasubramanian and his co-recipients David Klenerman and Pascal Meyer for their pioneering work in genome sequencing technologies.
Find out more -
Prof Sir Steve Jackson receives the 2026 Galen Medal in Therapeutics
14th May 2026
This award comes in recognition of his transformational work on the mechanisms of DNA repair, cell survival and the DNA-damage response (DDR), as well as for the development of the cancer-targeting drug Olaparib.
Find out more